CANCER AND LEUKEMIA GROUP B

该提案要求继续为机构提供资金。 纽约锡拉丘兹纽约州立大学健康科学中心于#年参加 癌症和白血病B组(CALGB)的研究活动。CALGB IS 一个多机构合作研究小组致力于 研究的系统规划、实施、分析和报告 适用于恶性疾病患者的治疗。的范围 CALGB的兴趣和我们的机构参与集中在治疗上 白血病、淋巴瘤以及肺癌、乳腺癌和胃肠道癌症， 以及基于实验室的评估。CALGB参加SUNY-HSC 是跨学科的，涉及将军和 胸外科、放射治疗、病理学、精神病学、细胞遗传学和 内科(血液学和肿瘤学)。纽约州立大学-HSC 积极参与CALGB计划的所有阶段。我们的人员 对集团科学和技术做出重大贡献，并在其中占有突出地位 行政领导、新的研究设计和主席职位、发展 以及执行试点研究和测试新的化疗药物 I期和II期试验中的药物除了 大于220个患者条目/年以分组协议。白血病 该小组的参考实验室位于我们机构。作为一名 这项提案提供的资金和我们的机构 承诺，受控患者的应收率， 可评估的实验性癌症治疗将维持在目前 高水平。临床研究的拓展和深化 我们机构的计划也将同样反映在深度和 我们对CALGB的科学和行政参与的广度 活动。因为我们与CALGB的机构参与是核心 在我们机构的跨学科癌症项目中，另外 医学教育将继续产生明显的有益效果。 学生、内务人员、护理人员以及继续 纽约州北部的医生教育。此外， 与CALGB的合作将有助于将 向庞大和多样化的患者群体提供医疗保健和专业知识。 通过我们既定的外展努力，癌症治疗方面的新进展 将迅速传播给中环新城的大批患者 约克市。

The proposal requests continuation funding for institutional participation of the SUNY Health Science Center at Syracuse, New York, in the research activities of Cancer and Leukemia Group B (CALGB). CALGB is a multi-institutional cooperative research group dedicated to the systematic planning, conduct, analysis, and reporting of research as applied to therapy of patients with malignant disease. The scope of interest of CALGB and our institutional participation focuses on therapy of leukemias, lymphomas, and cancers of the lung, breast, and GI tract, as well as laboratory based evaluations. CALGB participation at SUNY-HSC is interdisciplinary, involving the active participation of General and Thoracic Surgery, Radiotherapy, Pathology, Psychiatry, Cytogenetics and Internal Medicine (Hematology and Medical Oncology). The SUNY-HSC actively participates in all phases of the CALGB program. Our personnel contribute heavily to, and are prominent in, group scientific and administrative leadership, new study design and chairmanship, development and execution of pilot studies and the testing of new chemotherapeutic agents in phase I and phase II trials in addition to the accrual of greater the 220 patient entries/year to group protocols. The Leukemia Reference Laboratory for the group is located at our institution. As a result of the funding provided by this proposal and our institutional commitment, the accrual rate for patients entered into controlled, evaluable, experimental cancer therapy will be maintained at the current high level. The broadening and deepening of the clinical research program at our institution will similarly be reflected in the depth and breadth of our scientific and administrative involvement in CALGB activities. Since our institutional participation with CALGB is the core of the interdisciplinary cancer program at our institution, additional salutary effects will continue to be evident in the education of medical students, house officers, nursing staff as well as in the continuing education of physicians in Upstate New York. In addition, the collaboration with CALGB will help translate the most recent advances in medical care and expertise to a large and diversified patient population. Through our established outreach efforts, new advances in cancer therapy will be rapidly disseminated to large groups of patients in Central New York.